Today we announced the publication of the KINECT-PRO™ Phase 4 open-label study results in CNS Spectrums (@CambridgeCore ).

The 24-week study evaluated changes in patient-reported quality of life and functionality, in addition to tardive dyskinesia movement severity in adults receiving VMAT2 inhibitor treatment. These findings underscore the importance of evaluating the effect of tardive dyskinesia beyond movement severity because it can impact many aspects of patients’ lives.

https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-publication-kinect-protm